Skip to main content
×
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 18
  • Cited by
    This (lowercase (translateProductType product.productType)) has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Wolf, Jan Keipert, Dieter Motazedi, Heiko Ernst, Michael Nettleship, Joanne and Gooren, Louis 2017. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. The Aging Male, Vol. 20, Issue. 4, p. 225.

    Kim, Juhyun Coss, Christopher C. and Dalton, James T. 2014. Effect of para halogen modification of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides on metabolism and clearance. Archives of Pharmacal Research, Vol. 37, Issue. 11, p. 1464.

    Forsdahl, G. Vatne, H.K. Geisendorfer, T. and Gmeiner, G. 2013. Screening of testosterone esters in human plasma. Drug Testing and Analysis, Vol. 5, Issue. 11-12, p. 826.

    Di Luigi, Luigi Sgrò, Paolo Aversa, Antonio Migliaccio, Silvia Bianchini, Serena Botrè, Francesco Romanelli, Francesco and Lenzi, Andrea 2012. Concerns About Serum Androgens Monitoring During Testosterone Replacement Treatments in Hypogonadal Male Athletes: A Pilot Study. The Journal of Sexual Medicine, Vol. 9, Issue. 3, p. 873.

    Edelstein, Daniel and Basaria, Shehzad 2010. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opinion on Pharmacotherapy, Vol. 11, Issue. 12, p. 2095.

    Dandona, P. and Rosenberg, M. T. 2010. A practical guide to male hypogonadism in the primary care setting. International Journal of Clinical Practice, Vol. 64, Issue. 6, p. 682.

    Corona, G. Mannucci, E. Forti, G. and Maggi, M. 2009. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?. International Journal of Andrology, Vol. 32, Issue. 5, p. 431.

    Evans-Brown, Michael Kimergård, Andreas and McVeigh, Jim 2009. Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market. Drug Testing and Analysis, Vol. 1, Issue. 7, p. 323.

    Srinivas-Shankar, U. and Sharma, D. 2009. Testosterone treatment in elderly men. Advances in Therapy, Vol. 26, Issue. 1, p. 25.

    Minnemann, T. Schubert, M. Freude, S. Hübler, D. Gouni-Berthold, I. Schumann, C. Christoph, A. Oettel, M. Ernst, M. Mellinger, U. Krone, W. and Jockenhövel, F. 2008. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. Journal of Endocrinological Investigation, Vol. 31, Issue. 8, p. 718.

    Gooren, L. J. and Behre, H. M. 2008. Testosterone treatment of hypogonadal men participating in competitive sports. Andrologia, Vol. 40, Issue. 3, p. 195.

    Gooren, Louis J. 2008. Olympic sports and transsexuals. Asian Journal of Andrology, Vol. 10, Issue. 3, p. 427.

    Lunenfeld, Bruno Nieschlag, Eberhard Lunenfeld, Bruno and Nieschlag, Eberhard 2007. Testosterone therapy in the aging male. The Aging Male, Vol. 10, Issue. 3, p. 139.

    Yassin, Aksam A. 2007. The role for intramuscular testosterone injection in the gel era. Current Sexual Health Reports, Vol. 4, Issue. 3, p. 125.

    Nieschlag, Eberhard 2006. Testosterone treatment comes of age: new options for hypogonadal men. Clinical Endocrinology, Vol. 65, Issue. 3, p. 275.

    Yassin, Aksam A. and Saad, Farid 2006. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®). World Journal of Urology, Vol. 24, Issue. 6, p. 639.

    Morales, A. Nieschlag, E. Schubert, M. Yassin, A. A. Zitzmann, M. and Oettel, M. 2006. Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9–12 February 2006, Salzburg, Austria. The Aging Male, Vol. 9, Issue. 4, p. 221.

    Brady, B.M. Walton, M. Hollow, N. Kicman, A.T. Baird, D.T. and Anderson, R.A. 2004. Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Human Reproduction, Vol. 19, Issue. 11, p. 2658.

    ×
  • Print publication year: 2004
  • Online publication date: January 2010

14 - Pharmacology of testosterone preparations

Summary

Historical development of testosterone therapy

The first experimental proof that the testes produce a substance responsible for virility was provided by Berthold (1849). He transplanted testes from roosters into the abdomen of capons and recognized that the animals with the transplanted testes behaved like normal roosters: “They crowed quite considerably, often fought among themselves and with other young roosters and showed a normal inclination toward hens”. Berthold concluded that the virilizing effects were exerted by testicular secretions reaching the target organs via the bloodstream. Berthold's investigation is generally considered the origin of experimental endocrinology (Simmer and Simmer 1961). Following his observation various attempts were made to use testicular preparations for therapeutic purposes. The best known experiments are those by Brown-Séquard (1889), who tried testis extracts on himself which can at best have had placebo effects (Cussons et al. 2002). In the 1920s Voronoff transplanted testes from animals to humans for the purpose of rejuvenation (Voronoff 1920), but the effectiveness of his methods was disproven by a committee of the Royal Society London. The first testicular extracts with demonstrable biological activity were prepared by Loewe and Voss (1930) using the seminal vesicle as a test organ. Finally, the groundstone for modern androgen therapy was laid when steroidal androgens were first isolated from urine by Butenandt (1931), testosterone was obtained in crystalline form from bull testes by David et al. (1935) and testosterone was chemically synthesized by Butenandt and Hanisch (1935) and Ruzicka and Wettstein (1935).

Immediately after its chemical isolation and synthesis, testosterone was introduced into clinical medicine (unthinkable had it happened today) and used for the treatment of hypogonadism.

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Testosterone
  • Online ISBN: 9780511545221
  • Book DOI: https://doi.org/10.1017/CBO9780511545221
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×